Viewpoint News & Awards

Viewpoint Awarded $2 Million to Conduct a Phase 1 Clinical Trial at Mayo Clinic

September 20, 2019 | Coralville, IA. Viewpoint Molecular Targeting, Inc. was awarded a Phase II Small Business Innovation Research (SBIR) grant valued at $2 million from the National Cancer Institute (NCI). This award will support preclinical development and a phase 1 clinical imaging trial of a Viewpoint product in metastatic melanoma patients. The phase 1 clinical imaging trial will take place at Mayo Clinic in Rochester, MN and is an insightful key step of product development in advance of companion therapeutic trials.

This award is an excellent next step in advancing Viewpoint’s new therapy to the clinical stage. We could not be more excited about our progress and to expand our clinical trial sites.”–MICHAEL SCHULTZ, Viewpoint Co-Founder and Chief Science Officer

TRTC 2019 Consortium – Viewpoint is a Sponsor and CSO gives a Presentation

September 20, 2019 | Madison, WI. Michael K. Schultz, PhD, Co-Founder and Chief Science Officer of Viewpoint, presented  “212Pb & 203Pb Theranostics for Cancer” at the 2019 Targeted Radionuclide Therapy Consortium (TRTC) held at the University of Wisconsin-Madison. This three-day meeting focuses on advancing nuclear medicine science and education for the societal benefit of personalized healthcare, and personnel from fields of radiochemistry, radiology, radiation oncology, and medical physics are integrated at this event to fulfill this mission. Viewpoint Molecular Targeting is a proud Gold Industry Sponsor of the 2019 TRTC.

To see more: TRTC 2019

Viewpoint Research Published in Molecular Pharmaceutics

July 18, 2019 | Iowa City, IA. Viewpoint Molecular Targeting, Inc. and collaborators from the University of Iowa and the University of Missouri received acceptance notification from the peer-reviewed journal Molecular Pharmaceutics for the manuscript titled “Enhancing the efficacy of melanocortin 1 receptor-targeted radiotherapy by pharmacologically upregulating the receptor in metastatic melanoma.” Manuscript authors include: Li, Mengshi; Liu, Dijie; Lee, Dongyoul; Kapoor, Somya; Gibson-Corley, Katherine; Quinn, Thomas; Sagastume, Edwin; Mott, Sarah; Walsh, Susan; Acevedo, Michael; Johnson, Frances; and Schultz, Michael. This publication can be found in Molecular Pharmaceutics (Manuscript ID: mp-2019-00512p.R1.) 

Web access: 

Viewpoint CSO leads the DOE Lead-212 Users Meeting at SNMMI

June 22, 2019 | Anaheim, CA. Viewpoint Co-Founder and Chief Science Officer Michael K. Schultz, PhD led the Department of Energy Lead-212 User Meeting at the 2019 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held in Anaheim, CA. This event is a forum for the radiopharmaceutical community to come together and share respective success and challenges of introducing alpha-particle radionuclide therapy for cancer using lead-212. Dr. Schultz has consecutively led this event at the SNMMI annual meeting for the past three years. 

Viewpoint Awarded $300K NIH Phase I SBIR

June 1, 2019 | Coralville, IA. Viewpoint Molecular Targeting, Inc. was awarded a $300,000 Small Business Innovation Research (SBIR) Phase I grant by the National Institutes of Health (NIH). This marks a total of over $3M in funding and a total of 7 awards by the NIH to Viewpoint. Each award proves a vetting of Viewpoint’s approach and technology by recognized experts that serve on NIH review committees. These awards aid Viewpoint in the development and acceleration of image-guided therapy and diagnostic products for cancers, such as metastatic melanoma and neuroendocrine tumors.

NIH SBIR programs fund early stage small businesses that are seeking to commercialize innovative biomedical technologies. This competitive program helps small businesses participate in federal research and development to develop life-saving technologies and create jobs. For more information: About the NIH SBIR Program.

Viewpoint Biochemical Engineer Presents at the 2019 23rd International SRS Symposium

May 26, 2019 | Beijing, China. Viewpoint Biochemical Engineer Edwin Sagastume attended and presented at the international Society of Radiopharmaceutical Sciences symposium. The area of discussion for this congress is radiopharmaceutical science education and research with a goal of advancing excellence. By meeting in Beijing, Viewpoint continues to share and contribute its findings with the global radiopharmaceutical sciences community. The mutual benefit is outstanding. 

Viewpoint CSO Presents at the TWC in South Korea

March 2, 2019 | Jeju Island, South Korea. Viewpoint Co-Founder and Chief Science Officer Michael Schultz, PhD delivered an invited presentation at the 2019 Theranostics World Congress in Jeju, South Korea. This was the fifth occasion of the Theranostics World Congress, an event in attendance of leading experts with the point of discussing future prospects of expanding the use of theranostics in the health care system to new cancer types. Dr. Schultz presented “203Pb/212Pb Peptide Receptor Targeted Theranostics for Cancer” during the Next Generation Theranostics (from Chemists’ Point of View) – Alpha Emitters conference session. 

Viewpoint Teams with Voximetry to Improve Outcomes and Accelerate Clinical Trials for New Cancer Therapies

January 20, 2019 | Coralville, IA/Madison, WI. Viewpoint Molecular Targeting, Inc. and Voximetry, LLC announced the signing of a memorandum of collaboration to utilize Voximetry’s state of the art personalized nuclear medicine dosimetry software solution as a cutting edge tool for subject selection and dosimetry planning for upcoming clinical trials of Viewpoint’s new radiopharmaceutical therapies for cancer.

“We’re excited to be partnering with the Voximetry team. Our radiopharmaceutical therapies for cancer are entering the clinical trial phase of development when there is a growing understanding of the tremendous potential for ligand directed radionuclide-based therapies. Voximetry’s personalized dosimetry software is meeting the critical need for a widely deployable solution that can be implemented in the current operational paradigm of medical physics. The approach is envisioning a horizon that enables integration of a radionuclide-based dosimetry platform with current medical records and medical physics workflows. This is clearly the future of medical physics for theranostics.”–FRANCES L. JOHNSON, MD, Viewpoint Co-Founder and Chief Medical Officer

“Viewpoint is clearly emerging as a leader in the burgeoning field of alpha-particle targeted radionuclide therapy for cancer. The company is clearly not only looking at the technical-scaling challenges of conducting early stage clinical trials to demonstrate potential, but also working at an early stage of development to ensure that theranostic imaging and personalized dosimetry can be integrated into current medical records and transactional infrastructure. These goals are a clear match with the Voximetry dosimetry solution – that is, moving away from a dosimetry-consulting model to a highly accurate and adaptable solution that can be readily implemented in the normal therapeutic workflow. We could not be more delighted to partner with Viewpoint to ensure that their new radiopharmaceutical therapies can be adopted readily by medical institutions and clinics that rely on the electronic medical record.”–BRYAN BEDNARZ, PhD, Voximetry Chief Scientific Officer and Co-Founder

Voximetry, LLC,  was founded in Madison, WI in 2016 and is an early stage healthcare technology company that specializes in commercializing improvements related to nuclear medicine dosimetry. Voximetry’s patient-specific approach can accurately predict efficacy and adverse effects of radiopharmaceutical therapy, thereby improving patient outcomes.

Viewpoint Molecular Targeting, Inc., is an early stage radiopharmaceutical company that specializes in the development of alpha-particle targeted therapies for cancer. The company is based in Coralville, IA and is expanding radiopharmaceutical production operation facilities.

Viewpoint CSO “Spotlight Speaker” at World Molecular Imaging Congress

September 15, 2017 | Philadelphia, PA. Viewpoint Co-Founder and Chief Science Officer Michael Schultz, PhD was invited to speak at the Spotlight Session – Advancing Drug Discovery conference session of the World Molecular Imaging Congress. The spotlight sessions of the conference are designed to give attendees perspectives on current issues in molecular imaging. Dr. Schultz was invited to present his perspectives on the key role that University start-ups and small biotech companies play in advancing molecular imaging for drug development.

“It is very exciting for Viewpoint to be recognized by the World Molecular Imaging Society as a successful company. It was a remarkable session with perspectives ranging from large Pharma to contract research organizations.  I was delighted to take part.”–MICHAEL SCHULTZ, Viewpoint Co-Founder and Chief Science Officer

Viewpoint Awarded $2 Million NCI Contract

September 8, 2017 | Coralville, IA. Viewpoint Molecular Targeting, Inc., a University of Iowa start-up pharmaceutical company that has developed a novel therapy and companion diagnostic for metastatic melanoma, has been awarded a Phase II Small Business Innovation Research (SBIR) Contract Award valued at $2 million from the National Institutes of Health (NIH) to support pre-clinical studies of its lead product, VMT01. The company has successfully secured $900K in previously awarded Phase I SBIR grants and contracts. “We value the NIH’s continued recognition of the importance of our products and its support of our development program. We are excited with the progress we are making to bring our products forward,” said Edwin Sagastume, Viewpoint Biochemical Engineer and University of Iowa graduate.

About Viewpoint Molecular Targeting

Viewpoint Molecular Targeting develops therapies and diagnostics for cancer, with a focus on metastatic melanoma and neuroendocrine tumors. It’s lead products, VMT01 and VMT-α-NET, are injectable radiopharmaceuticals. The products can be used to determine the location and extent of cancerous tumors in the body and then the therapeutic forms can be used to direct a therapeutic dose of radiation precisely to cancer cells in the body. This represents a new class of drugs called theranostics.

Viewpoint has successfully secured over $6 million through seed capital investments, NIH SBIR grants, Iowa Economic Development Authority Demonstration Funds, Innovation Iowa Corporation Matching Funds, and business pitch competition victories. The current award sends the company into clinical trials for its lead products, with other cancer therapy products in the development pipeline.

About NIH SBIR Program

The NIH SBIR program funds early stage small businesses that are seeking to commercialize innovative biomedical technologies. This competitive program helps small business participate in federal research and development to develop life-saving technologies and create jobs.

See more: UIHC

Viewpoint’s products are currently under development and therefore not approved by the FDA.

About Viewpoint

Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. Our novel image-guided therapies enable a personalized approach to select patients that can benefit most and to optimize treatment planning for our targeted therapies. Our unique “theranostic” agents possess properties for both diagnostic imaging and therapy for cancer, personalizing the selection of patients and optimizing patient care.

Recent Posts